Head-To-Head Survey: IN8bio (NASDAQ:INAB) versus XBiotech (NASDAQ:XBIT)

XBiotech (NASDAQ:XBIT) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Valuation and Earnings

This table compares XBiotech and IN8bio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54 million	($1.50)	-1.51
IN8bio	N/A	N/A	-$19.44 million	($4.45)	-0.32

XBiotech is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares XBiotech and IN8bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-27.80%	-26.67%
IN8bio	N/A	-111.30%	-88.07%

Risk & Volatility

XBiotech has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for XBiotech and IN8bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1	0	0	0	1.00
IN8bio	1	1	1	0	2.00

IN8bio has a consensus price target of $4.00, suggesting a potential upside of 183.69%. Given IN8bio’s stronger consensus rating and higher possible upside, analysts plainly believe IN8bio is more favorable than XBiotech.

Insider and Institutional Ownership

55.7% of XBiotech shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 30.8% of XBiotech shares are held by company insiders. Comparatively, 9.5% of IN8bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

IN8bio beats XBiotech on 6 of the 11 factors compared between the two stocks.

About XBiotech

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager
platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications.